According to the report “The Ophthalmic Pharmaceutical Market Outlook to 2014” available at http://www.reportbuyer.com/
Subsequent generic incursion coupled with the increasing legislative priority towards healthcare reform across the globe will hurt market expansion and growth of ophthalmic franchises of leading pharmaceutical companies. Driven by good efficacy, Roche/Genentech's Lucentis and Allergan/Inspire's Restasis is expected to dominate the treatment of wet AMD and dry eye markets respectively.
However the 158 page report expects worldwide sales of ophthalmology treatments to remain roughly flat during 2008-14. This study provides a competitive analysis of the leading brands within each indication, enabling the identification of the growth brands, major sub-therapy areas and leading players through to 2014.
The report “The Ophthalmic Pharmaceutical Market Outlook to 2014” is available from Report Buyer at:
Report Buyer product ID: RBI00327
About Report Buyer.
# # #
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare.